The securities described above are being offered by Kite pursuant to a shelf registration statement (including a prospectus) filed on December 8, 2015 with the Securities and Exchange Commission(SEC), which has become automatically effective. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available for free on the SEC's website at. Cowen and Company, LLC and RBC Capital Markets, LLC are acting as joint book-running managers, and Stifel is acting as co-manager. Jefferies LLC and Citigroup Global Markets Inc. are acting as lead book-running managers for the offering. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 543,750 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about December 15, 2015, subject to customary closing conditions. The gross proceeds to Kite from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $250.1 million. 10, 2015 (GLOBE NEWSWIRE) - Kite Pharma, Inc. (Nasdaq:KITE) today announced the pricing of an underwritten public offering of 3,625,000 shares of its common stock at a price to the public of $69.00 per share. Kite Pharma Announces Pricing of Public Offering of Common Stock
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |